Patents by Inventor S. Brogger Christensen

S. Brogger Christensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tissue specific prodrug
    Patent number: 6545131
    Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-&ggr;-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: April 8, 2003
    Assignee: The Johns Hopkins University
    Inventors: John T. Isaacs, Samuel R. Denmeade, S. Brogger Christensen
  • Tissue specific prodrug
    Patent number: 6504014
    Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-&ggr;-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: January 7, 2003
    Assignee: The John Hopkins University
    Inventors: John T. Isaacs, Samuel R. Denmeade, S. Brogger Christensen, Hans Lilja
  • Tissue specific prodrug
    Patent number: 6410514
    Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-&ggr;-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: June 25, 2002
    Assignee: The Johns Hopkins University
    Inventors: John T. Isaacs, Samuel R. Denmeade, S. Brogger Christensen, Hans Lilja
  • Tissue specific prodrug
    Patent number: 6265540
    Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-&ggr;-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: May 19, 1998
    Date of Patent: July 24, 2001
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: John T. Isaacs, Samuel R. Denmeade, S. Brogger Christensen, Hans Lilja